We have developed a novel vector constructed with pDNA, polyethylenimine (PEI), and mucin 1 (MUC1) aptamer for tumor-targeted gene delivery. The MUC1 aptamer and non-specific aptamer were employed to coat the pDNA/PEI complexes electrostatically and stable nanoparticles were formed. The addition of a non-specific aptamer to the pDNA/PEI complex decreased gene expression in the human lung cancer cell line, A549 cells expressing MUC1 regularly. At the same time, the pDNA/PEI/MUC1 aptamer complex showed higher gene expression than pDNA/PEI/non-specific aptamer complex. Furthermore, the pDNA/PEI/MUC1 aptamer complex showed markedly high gene expression in tumor-bearing mice; thus, pDNA/PEI/MUC1 aptamer complexes are useful as a tumor-targeted gene delivery system with high transfection efficiency.
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Introduction
In the field of gene delivery, polyethylenimine (PEI) is a common cationic polymer with high transfection efficiency under in vitro and in vivo conditions among non-viral vectors (Boussif, et al., 1995; Godbey, et al., 1999; Kircheis, et al., 2001; Kichler, et al., 2001; Itaka, et al., 2004 ) . The pDNA/PEI complex, however, binds non-specifically to negatively charged proteoglycans on cell membranes and it is difficult to use the cationic pDNA/PEI complex as the targeted gene delivery system (Lemkine and Demeneix, 2001; Demeneix and Behr, 2005) . For cell-specific gene delivery, cell type-specific surface molecules and their antibodies would be useful, and a number of cell-specific gene delivery vectors have been developed (Germershaus, et al., 2006; Chiu, et al., 2004; Liu, et al., 2007) . For cancer gene therapy, tumor suppressor genes such as p53 gene and suicide genes such as herpes simplex virus thymidine kinase gene were well studied; and those genes reported to suppress tumor growth by tumor specific gene delivery vector such as transferrin-modified cationic liposome (Nakase, et al., 2005; Neves, 2006) .
Aptamers are a family of RNA-or DNA-based oligonucleotides 20-50 nt in length that can specifically bind to selected targets (Guo, et al., 2010) . They have often been described as nucleic acid versions of antibodies. However, aptamers unlike antibodies, have yet to elicit immunogenicity in vivo and these molecules are readily amenable to chemical synthesis and can be modified easily during the synthesis process, making them more adaptable for 4 different applications (Eyetech Study Group, 2003; Chan, et al., 2008; Alexander, et al., 2005; Gilbert, et al., 2007; Apte, et al., 2007) .
In a previous study, we developed some ternary complexes of pDNA/PEI coated with polynucleotides such as polyadenylic acid (polyA) and polyinosinic-polycytidylic acid (polyIC) (Kurosaki, et al., 2009) . It was demonstrated that aptamers could coat pDNA/PEI complexes and the aptamer-coated complex would be taken up by the cells via aptamer-based molecular recognitions. The mucin 1 (MUC1) is unique to tumor cells and overexpressed in most of invasive breast carcinomas, indicating that MUC1 aptamer would be suitable for tumor targeting (Rahn, et al., 2001) .
In this experiment, we constructed pDNA/PEI/aptamer complexes with MUC1 aptamer for tumor-targeted gene delivery systems. Then, the pDNA/PEI/MUC1 aptamer complex showed high gene expressions of the plasmid-borne luciferase gene in A549 cells expressing MUC1 regularly under in vitro and in vivo conditions.
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Materials and Methods
Chemicals
PEI (branched form, average molecular weight of 25,000) was purchased from Aldrich Chemical Co. (Milwaukee, WI, USA). Fetal bovine serum (FBS) was obtained from Biosource International Inc. (Camarillo, CA, USA). RPMI 1640, Opti-MEM I, antibiotics (penicillin 100 U/mL and streptomycin 100 g/mL), and other culture reagents were obtained from GIBCO BRL (Grand Island, NY, USA). MUC1 aptamer (5'-GAAGTGAAAATGACAGAACACAACA-3') and a non-specific 25 base-long DNA aptamer composed of GATC repeats, according to a previous report (Ferreira, et al., 2009), were purchased from Hokkaido System Science Co., Ltd. (Hokkaido, Japan). All other chemicals were of the highest purity available.
Preparation of pDNA and Complexes
pCMV-Luc was constructed by subcloning the Hind III/Xba I firefly luciferase cDNA fragment from the pGL3-control vector (Promega, Madison, WI, USA) into the polylinker of the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA). The pDNA was amplified using an 
Physicochemical Property of the Complexes
The particle sizes and ζ-potentials of the pDNA/PEI/aptamer complexes were measured using a Zetasizer Nano ZS (Malvern Instruments, Ltd., United Kingdom). The number-fractioned mean diameter is shown.
To determine complex formations, 10 µL aliquots of complex solution containing 1 µg pDNA were mixed with 2 µL loading buffer (30% glycerol and 0.2% bromophenol blue) and loaded onto a 0.8% agarose gel containing 0.03% ethidium bromide. For the assessment of complex dissociation, 3 µg of heparin was added to pDNA/PEI complex. Electrophoresis 
In Vitro Transfection Experiments
The human lung cancer cell line, A549 cells, was obtained from the Cell Resource Center Absorbance was measured using a microplate reader at 570 nm. Luciferase activity was indicated as relative light units (RLU) per mg protein.
In Vivo Transfection Experiments
Animal care and experimental procedures were performed in accordance with the , the mice were injected intratumorally with various complexes containing 20 g pDNA at a volume of 100 L per tumor. At 24 h following injection, the mice were sacrificed and the tumors were dissected and homogenized in lysis buffer. The homogenates were centrifuged at 15000 rpm (Kubota 3700; Kubota, Tokyo, Japan) for 5 min. The supernatants were used for luciferase assays, as described above. Luciferase activity was indicated as RLU per gram of tissue.
Statistical Analysis
Multiple comparisons among groups were made by Sheffe's test. P < 0.05 indicated significance.
3. Results
Physicochemical Characteristics
The size and ζ-potential of the complexes were determined (Fig. 1) . The ζ-potential means surface charge of the particles; + means cationic surface charge and -means anionic surface charge. The pDNA/PEI complex was about 52.9 nm particle size with +56 mV ζ-potential. By the addition of aptamers, the ζ-potential was concentration-dependently decreased and reached a plateau at a weight ratio 1:1:6 of pDNA: PEI: aptamer. Addition of aptamers aggregated the pDNA/PEI complex at weight ratio, 1:1:1. Furthermore, MUC1
aptamer increased size of the complex at weight ratio 1:1:2. Conversely, the complexes with other weight ratios had almost 48-75 nm particle size.
Complex formations were examined by a gel retardation assay (Fig. 2) . In the lane of naked pDNA, bands of pDNA were detected on agarose gel. On the other hand, in the lanes of pDNA/PEI complex and pDNA/PEI/aptamer complexes, no band was detected.
Furthermore, the addition of heparin to pDNA/PEI complex released pDNA from the complex and bands of pDNA were detected clearly.
In vitro transfection efficiencies
A human lung adenocarcinoma epithelial cell line, A549 cells, regularly expressing MUC1, was transfected with various complexes and gene expression of luciferase carried by 10 the plasmid vector was evaluated (Fig. 3) . The pDNA/PEI complex showed 6.33×10 9 RLU/mg protein in transgene efficiency. In contrast, the high transgene efficiency of pDNA/PEI complexes was significantly decreased in a concentration-dependent manner by the addition of non-specific aptamer (P < 0.01). The pDNA/PEI/MUC1 aptamer complexes showed significantly higher gene expressions than pDNA/PEI complex at weight ratios 1:1:0.25, 1:1:0.5, and 1:1:1 (P < 0.01) and the gene expressions of pDNA/PEI/MUC1 aptamer complexes were higher than the pDNA/PEI/non-specific aptamer complexes at all weight ratios. The highest gene expression was observed at a weight ratio 1:1:0.5.
In vivo transfection efficiencies
A549 cells were administrated to mice and tumor-bearing model mice were developed.
The pDNA/PEI complex and pDNA/PEI/aptamer complexes at a weight ratio 1:1:0.5 were injected into the tumor. Twenty-four hours after injection, the transgene efficiencies in the tumor were evaluated, as shown in Fig. 4 . A high gene expression was observed in mice treated with pDNA/PEI/MUC1 aptamer complexes and was significantly higher than the gene expressions of pDNA/PEI complex and pDNA/PEI/non-specific aptamer complex-treated mice (P < 0.05 and P < 0.01, respectively).
Discussion
MUC1 is a membrane-tethered mucin expressed on the surface of epithelial cells lining mucosal surfaces (Kim and Lillehoj, 2008) . Overexpression of MUC1 by most carcinomas and in particular by breast cancers has been reported and correlates with high metastatic potential and poor survival (Gendler, 2001 ). An underglycosylated form of MUC1 that is unique to tumor cells is overexpressed in virtually all invasive breast carcinomas, making MUC1 a prime candidate for several promising therapeutic vaccine strategies and a potential marker for prognosis (Rahn, et al., 2001 ).
In previous reports, MUC1 antibody was developed and used in tumor-specific drug delivery systems (Singh and Bandyopadhyay, 2007; Moase, et al., 2011) . Recently, MUC1
aptamers were also developed and reported to show high selectivity (Ferreira, et al., 2009; Savla, et al., in press ); however, there are few reports about gene delivery systems using MUC1 aptamer. In the previous study, we developed some ternary complexes of pDNA/PEI coated by polynucleic acid, such as polyadenylic acid (polyA) and polyinosinic-polycytidylic acid (polyIC) (Kurosaki, et al., 2009 ). We also successfully constructed pDNA/PEI/MUC1 aptamer complexes (Japanese Patent Application No. 2010-043186) . In this experiment, we Strong anionic surface charges may repulse the cellular membrane and the rebound might be larger than the binding strength of MUC1 aptamer to MUC1.
Aptamers on the complex surface were also anticipated from the physicochemical properties of the complexes. The addition of aptamer did not disrupt the structure of pDNA/PEI complex, as shown in Fig. 2 . However, the aptamer reversed the charge from positive to negative indicating a concentrated distribution of aptamer outside of the particles.
MUC1 aptamer increased size of the pDNA/PEI complex at weight ratio, 1:1:2, even if non-specific aptamer did not increase at same weight ratio. It may be caused by the steric structure of MUC1 aptamer.
The pDNA/PEI/MUC1 aptamer complex with a weight ratio of 1:1:0.5, which showed highest gene expressions in vitro, was administered to tumor-bearing mice and gene expressions in vivo were evaluated. The pDNA/PEI/MUC1 aptamer complexes showed significantly higher gene expressions in the tumor than pDNA/PEI complex and pDNA/PEI/non-specific aptamer complex after intratumoral injection (P < 0.05 and P < 0.01, 13 respectively). The results indicate that the pDNA/PEI/MUC1 aptamer complex may be useful for tumor-targeted gene delivery systems.
For the tumor therapy, most current therapies are non-specific, with surgery, radiation, and chemical ablation having the potential to cause damage to surrounding tissue. Similarly non-specific transfection should cause unexpected critical side effects. In this experiment, we constructed pDNA/PEI/MUC1 aptamer complex for tumor specific gene delivery.
Furthermore, this pDNA/PEI/aptamer complex could easily change targeting cells by selection of aptamer and could achieve cell-specific gene transfer. The coating and targeting system may be a novel platform technology for targeted gene delivery.
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Conclusion
In this experiment, we constructed a novel tumor-targeted gene delivery vector, pDNA/PEI/MUC1 aptamer complex. MUC1 aptamer could coat cationic pDNA/PEI complex, electorostatically. The pDNA/PEI/MUC1 aptamer complexes showed higher gene expressions than pDNA/PEI/non-specific aptamer complexes on the A549 cells which are expressing MUC1 regularly in in vitro and in vivo conditions. The coating system could be applied to other aptamers and may be a novel platform technology for targeted gene delivery. pDNA/PEI complex and pDNA/PEI/aptamer complexes with weight ratio 1:1:0.5 were administrated into the tumors of mice. Twenty-four hours after administration, the tumors were dissected and luciferase activities were evaluated. Each bar represents the mean ± S.E. of three to five experiments. *: P < 0.05 vs pDNA/PEI complex, ##: P < 0.01.
